Intellectual Ventures

Nathan Myhrvold has led the firm as CEO since founding it in 2000 alongside Edward Jung. The investment and acquisition committees include seasoned patent attorneys and technologists who evaluate both the technical merit and the licensing potential of patent portfolios before committing capital.

Intellectual Ventures does not take equity stakes in startups. It builds or buys patent rights and then licenses those inventions to operating companies. The firm's own lab creates prototypes, but commercialization typically occurs through separate spinout entities, not through IV's balance sheet.

The firm manages dedicated patent-acquisition funds for institutional limited partners. Investors commit capital to these vehicles, which then acquire patents directly. The funds are not fund-of-funds structures, and IV's primary activity is sourcing and monetizing IP assets.

The firm's publicly disclosed patent holdings span a wide technical range, but it has not claimed a focus on consumer-packaged goods, fashion, or entertainment IP. The portfolio concentrates on physics- and engineering-intensive fields where patent protection provides a substantial barrier to unlicensed commercial use.

TerraPower was originally incubated inside Intellectual Ventures' Invention Science Fund as a nuclear reactor design project. It subsequently spun out as an independent company, raised its own capital from external investors, and now operates with its own board and management — though Nathan Myhrvold remains a co-founder.

The firm has supported global health and development invention projects through a related entity called Global Good, which was funded alongside Bill Gates. Global Good focuses on neglected-disease diagnostics, vaccine delivery, and agricultural technologies for low-income countries, operating as a separate collaborative initiative.

The firm has not typically co-invested alongside venture capital or private equity managers in operating companies. Its model is built around being the patent-holder and licensor, which makes it more analogous to a royalty-based financing partner than a traditional equity co-investor.